skip to the content

AVAiL: continued PFS benefit in the maintenance phase (an exploratory retrospective analysis)9

AVAiL: Avastin prolonged PFS versus placebo

AVAiL: Avastin prolonged PFS versus placebo at both 7.5mg/kg and 15mg/kg doses9

  • In AVAiL, Avastin was given with cisplatin/gemcitabine for six cycles and then as a single agent until PD (maintenance).
  • A retrospective analysis of AVAiL investigated PFS following Avastin or placebo in the maintenance phase of this trial (i.e. PFS was measured from the end of the Avastin/placebo plus cisplatin/gemcitabine phase to PD or death).
  • Avastin used as single-agent maintenance therapy appears to confer clinical benefit beyond the chemotherapy phase.
  • PFS was measured from last day of last cycle of cisplatin/gemcitabine plus Avastin/placebo to PD or death.
 

Next

Back